乳腺癌治疗后随访期间乳腺活检的发生率与结局
近距离放疗、辅助化疗与活检风险升高独立相关,内分泌治疗与风险降低相关;活检患者中分别有29.8%和23.2%接受了后续癌症治疗。
要点
- 乳腺癌治疗后随访活检率较高,商业保险队列10年达23.4%。
- 近距离放疗较全乳放疗与更高活检风险独立相关。
- 活检后约1/4至1/3患者接受了后续癌症治疗。
核心结论
- 乳腺癌治疗后随访期间乳腺活检并不少见,且部分活检后需后续癌症治疗。
主要发现
- 商业保险队列5年和10年活检累积发生率分别为14.7%和23.4%,SEER-Medicare队列分别为11.8%和14.9%。
- 近距离放疗者5年活检发生率在商业保险队列为24.0%、SEER-Medicare队列为25.0%,高于全乳放疗者的16.7%和15.1%。
- 多因素调整后,近距离放疗与活检风险升高独立相关(商业保险HR 1.53,95%CI 1.38-1.70,P<.001;SEER-Medicare HR 1.76,95%CI 1.63-1.91,P<.001)。
- SEER-Medicare队列中辅助化疗与活检风险升高独立相关(HR 1.31,95%CI 1.25-1.37,P<.001),年龄>85岁较66-69岁风险降低(HR 0.40,95%CI 0.36-0.44,P<.001)。
- 内分泌治疗与活检风险降低独立相关(商业保险HR 0.88,95%CI 0.82-0.93,P<.001;SEER-Medicare HR 0.91,95%CI 0.85-0.97,P=.002)。
临床怎么用
- 治疗决策时可参考随访活检的累积风险数据,向患者说明幸存者随访预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: No comprehensive data are available regarding the frequency of breast biopsies performed during follow-up of treatment for invasive breast cancer. OBJECTIVE: To determine how often patients treated for breast cancer require breast biopsies during follow-up. DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based cohort study included 41 510 patients 64 years or younger in a commercial insurance database and 80 369 patients 66 years or older in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Patients were diagnosed with incident invasive breast cancer (stages I-III) from January 1, 2000, through December 31, 2011. Diagnosis and procedural codes were used to identify biopsy rates during follow-up. Data were analyzed from March 3 through October 3, 2017. MAIN OUTCOMES AND MEASURES: Cumulative incidence and adjusted risk of breast biopsy and subsequent breast cancer treatment were calculated using the Kaplan-Meier method and Cox proportional hazards regression. All statistical tests were 2 sided. RESULTS: Among the 121 879 patients in the study population, 5- and 10-year overall incidences of breast biopsy were 14.7% and 23.4%, respectively, in the commercial insurance cohort and 11.8% and 14.9%, respectively, in the SEER-Medicare cohort. The 5-year estimated incidence of breast biopsy was higher among women treated with brachytherapy (24.0% in the commercial insurance and 25.0% in the SEER-Medicare cohorts) than among those treated with whole-breast irradiation (16.7% in the commercial insurance and 15.1% in the SEER-Medicare cohorts) and persisted after multivariate adjustment in the commercial insurance (hazard ratio [HR], 1.53; 95% CI, 1.38-1.70; P < .001) and SEER-Medicare (HR, 1.76; 95% CI, 1.63-1.91; P < .001) cohorts. Adjuvant chemotherapy use (HR, 1.31; 95% CI, 1.25-1.37; P < .001) and patient age (>85 vs 66-69 years; HR, 0.40; 95% CI, 0.36-0.44; P < .001) in the SEER-Medicare cohort and endocrine therapy in the commercial insurance (HR, 0.88; 95% CI, 0.82-0.93; P < .001) and SEER-Medicare (HR, 0.91; 95% CI, 0.85-0.97; P = .002) cohorts were independently associated with biopsy. After unilateral mastectomy, the estimated 5-year contralateral breast biopsy rates were 10.4% and 7.7% in the commercial insurance and SEER-Medicare cohorts, respectively. Of the patients with breast biopsy, 1239 of 4158 patients (29.8%) in the commercial insurance cohort and 2258 of 9747 patients (23.2%) in the SEER-Medicare cohort underwent subsequent cancer treatment. CONCLUSIONS AND RELEVANCE: These data on the need for breast biopsies during follow-up and subsequent treatments from a large cohort of women with commercial insurance and Medicare can be used in the context of therapy-planning discussions and survivorship expectations for patients with breast cancer.
引用
- van la Parra RFD, Liao K, Smith BD, et al. Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer. JAMA Surg. 2018. PMID: 29387884. doi:10.1001/jamasurg.2017.5572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。